A Phase 1/2a Single Dose and 28-day Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream 0.5% and 0.15% in Adults With Mild to Moderate Chronic Plaque Psoriasis
Phase of Trial: Phase I/II
Latest Information Update: 05 Jul 2018
At a glance
- Drugs ARQ-151 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Arcutis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 25 Jun 2018 Status changed from active, no longer recruiting to completed.
- 30 Mar 2018 Status changed from recruiting to active, no longer recruiting.